Anti-protein aggregation is a potential target for preventing delayed neuronal death after transient ischemia

Medical Hypotheses

Volumn 73, Issue 6, 2009, Pages 994-995

  Ge, Pengfei ^a,b   Luo, Yinan ^b   Wang, Haifeng ^b   Ling, Feng ^a  

^a CAPITAL MEDICAL UNIVERSITY   (China)

^b JILIN UNIVERSITY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

4 PHENYLBUTYRIC ACID; AMINO ACID DERIVATIVE; BINDING PROTEIN; CHAPERONE; GELDANAMYCIN; GLYCINE ETHYL ESTER; POLYQ BINDING PEPTIDE; PROTEASOME; TREHALOSE; UNCLASSIFIED DRUG;

ALZHEIMER DISEASE; ARTICLE; CELL PROTECTION; CELL STRESS; CYTOTOXICITY; DEGENERATIVE DISEASE; DRUG MECHANISM; HUMAN; NERVE CELL NECROSIS; NONHUMAN; PRIORITY JOURNAL; PROTEIN AGGREGATION; PROTEIN CONFORMATION; PROTEIN FOLDING; PROTEIN FUNCTION; PROTEIN STABILITY; PROTEIN TARGETING; TRANSIENT ISCHEMIC ATTACK;

BRAIN ISCHEMIA; CELL DEATH; HUMANS; NERVE TISSUE PROTEINS; NEURONS; PROTEIN BINDING;

EID: 70449706439     PISSN: 03069877     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.mehy.2008.10.041     Document Type: Article

References (29)

1. Albers G.W., Caplan L.R., Coull B., et al. Transient ischemic attack - proposal for a new definition. N Engl J Med 347 21 (2002) 1713-1716
2. Kirino T. Delayed neuronal death in the gerbil hippocampus following ischemia. Brain Res 239 1 (1982) 57-69
3. Hu B.R., Martone M.E., Jones Y.Z., and Liu C.L. Protein aggregation after transient cerebral ischemia. J Neurosci 20 9 (2000) 3191-3199
4. Hu B.R., Janelidze S., Ginsberg M.D., et al. Protein aggregation after focal brain ischemia and reperfusion. J Cereb Blood Flow Metab 21 7 (2001) 865-875
5. Giffard R.G., Xu L., and Zhao H. Chaperones, protein aggregation, and brain protection from hypoxic/ischemic injury. J Exp Biol 207 Pt 18 (2004) 3213-3220
6. Ge P., Luo Y., Liu C., et al. Protein aggregation and proteasome dysfunction after brain ischemia. Stroke 38 12 (2007) 3230-3236
7. McNaught K.S., and Olanow C.W. Protein aggregation in the pathogenesis of familial and sporadic Parkinson's disease. Neurobiol Aging 27 4 (2006) 530-545
8. Reixach N., Deechongkit S., Jiang X., et al. Tissue damage in the amyloidoses: transthyretin monomers and nonnative oligomers are the major cytotoxic species in tissue culture. Proc Natl Acad Sci USA 101 9 (2004) 2817-2822
9. Gales L., Cortes L., Almeida C., et al. Towards a structural understanding of the fibrilization pathway in Machado-Joseph's disease: trapping early oligomers of non-expanded ataxin-3. J Mol Biol 353 3 (2005) 642-654
10. Burdick D., Soreghan B., Kwon M., et al. Assembly and aggregation properties of synthetic Alzheimer's A4/beta amyloid peptide analogs. J Biol Chem 267 1 (1992) 546-554
11. Kim Y.J., and Takahashi R. Role of polyunsaturated fatty acids for misfolding protein aggregations: implication for neurodegenerative diseases. Ann N Y Acad Sci 1086 11 (2006) 11-20
12. Gregersen N., Bolund L., and Bross P. Protein misfolding, aggregation, and degradation in disease. Mol Biotechnol 31 2 (2005) 141-150
13. Stefani M., and Dobson C.M. Protein aggregation and aggregate toxicity: new insights into protein folding, misfolding diseases and biological evolution. J Mol Med 81 11 (2003) 678-699
14. Kopito R.R. Aggresomes, inclusion bodies and protein aggregation. Trends Cell Biol 10 12 (2000) 524-530
15. Hu B.R., Janelidze S., Ginsberg M.D., et al. Protein aggregation after focal brain ischemia and reperfusion. J Cereb Blood Flow Metab 21 7 (2001) 865-875
16. Nandi D., Tahiliani P., Kumar A., et al. The ubiquitin-proteasome system. J Biosci 31 1 (2006) 137-155
17. Bukau B., Weissman J., and Horwich A. Molecular chaperones and protein quality control. Cell 125 3 (2006) 443-451
18. Chaudhuri T.K., and Paul S. Protein-misfolding diseases and chaperone-based therapeutic approaches. FEBS J 273 7 (2006) 1331-1349
19. Liberek K., Lewandowska A., and Zietkiewicz S. Chaperones in control of protein disaggregation. EMBO J 27 2 (2008) 328-335
20. Griffiths H.H., Morten I.J., and Hooper N.M. Emerging and potential therapies for Alzheimer's disease. Expert Opin Ther Targets 12 6 (2008) 693-704
21. Steffan J.S., and Thompson L.M. Targeting aggregation in the development of therapeutics for the treatment of Huntington's disease and other polyglutamine repeat diseases. Expert Opin Ther Targets 7 2 (2003) 201-213
22. de Almeida S.F., Picarote G., Fleming J.V., et al. Chemical chaperones reduce endoplasmic reticulum stress and prevent mutant HFE aggregate formation. J Biol Chem 282 38 (2007) 27905-27912
23. Kubota K., Niinuma Y., Kaneko M., et al. Suppressive effects of 4-phenylbutyrate on the aggregation of Pael receptors and endoplasmic reticulum stress. J Neurochem 97 5 (2006) 1259-1268
24. Davies J.E., Sarkar S., and Rubinsztein D.C. Trehalose reduces aggregate formation and delays pathology in a transgenic mouse model of oculopharyngeal muscular dystrophy. Hum Mol Genet 15 1 (2006) 23-31
25. Arora A., Ha C., and Park C.B. Inhibition of insulin amyloid formation by small stress molecules. FEBS Lett 564 1 (2004) 121-125
26. Tanaka M., Machida Y., Niu S., et al. Trehalose alleviates polyglutamine-mediated pathology in a mouse model of Huntington disease. Nat Med 10 2 (2004) 148-154
27. Popiel H.A., Nagai Y., Fujikake N., et al. Delivery of the aggregate inhibitor peptide QBP1 into the mouse brain using PTDs and its therapeutic effect on polyglutamine disease mice. Neurosci Lett (2008) [Epub ahead of print]
28. Shen H.Y., He J.C., Wang Y., et al. Geldanamycin induces heat shock protein 70 and protects against MPTP-induced dopaminergic neurotoxicity in mice. J Biol Chem 280 48 (2005) 39962-39969
29. Ito L., Kobayashi T., Shiraki K., et al. Effect of amino acids and amino acid derivatives on crystallization of hemoglobin and ribonuclease A. J Synchrotron Radiat 15 Pt 3 (2008) 316-318